Add-On Therapies in Cardiovascular Disease: Reviewing ICER's Report and the Potential Effect on Payers.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32463778.
- Also identified by DOI 10.18553/jmcp.2020.26.6.786 and PMC identifier 10391064.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No outside funding supported this commentary. The authors have nothing to disclose.
Medical subject headings
- Cardiovascular Diseases
- Cost-Benefit Analysis
- Eicosapentaenoic Acid
- Hemorrhage
- Rivaroxaban